We are pioneers in targeting C1q, the initiating molecule of the classical complement pathway. By stopping the start of this pathway, our C1q inhibitors are designed to treat multiple complement-mediated diseases of the body, brain, and eye.Our Platform
Our Path. Many Opportunities.
Our upstream complement approach targeting C1q acts as an "on/off switch" designed to block all downstream components of the classical complement pathway. Aberrant activation of C1q can lead to tissue damage in antibody-mediated autoimmune diseases and complement-mediated neurodegenerative diseases.
We are leading the development of novel inhibitors that are designed to block C1q and the entire classical complement pathway. We are developing these therapeutics for autoimmune and neurodegenerative diseases of the body, brain, and eye.Our Pipeline